Clinical Trials Logo

Small Cell Lung Cancer clinical trials

View clinical trials related to Small Cell Lung Cancer.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 3

NCT ID: NCT04073550 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

Start date: October 31, 2019
Phase: Phase 3
Study type: Interventional

Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.

NCT ID: NCT03890055 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride

Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

This study was designed to investigate the efficacy and side effects of combining erlotinib with classical EC/EP chemotherapy regimens.

NCT ID: NCT03780283 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

Investigations prospectively collected the SCLC patients who received current standard first-line treatment, the response was not progression disease(PD). and then participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity. This regimen is compared to the effects a observation without treatment after the first-line therapy. The aim of the study is therefore to evaluate the efficacy and safety of Anlotinib as maintenance treatment after first-line chemotherapy in SCLC patients.

NCT ID: NCT03651219 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

Start date: September 8, 2018
Phase: Phase 3
Study type: Interventional

The aim of the study is to evaluate the safety and efficacy of apatinib mesylate tablets and chemotherapy drug Irinotecan in treatment of recurrent SCLC stage IIIB&IV patients. It is a randomized controlled clinical trial.

NCT ID: NCT02980809 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

Start date: March 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether topotecan plus apatinib are superior to topotecan alone as second-line therapy in small-cell lung cancer.

NCT ID: NCT02875457 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin

Start date: September 2016
Phase: Phase 3
Study type: Interventional

Apatinib has been approved as a second-line treatment for advanced gastric cancer. Several phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less toxic side effects and better patient tolerance. However, the clinical application of apatinib in small cell lung cancer is still lack of evidence-based medicine. Etoposide and cisplatin chemotherapy is the first-line treatment for small-cell lung cancer. The purpose of this multicenter, randomized, prospective study is to investigate the efficacy and safety of apatinib as the maintenance therapy for extensive stage small cell lung cancer after combined with etoposide and cisplatin chemotherapy.